Clinical Trials Logo
  1. Home
  2. Malaria, Vivax
  3. NCT02751294

A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution

Malaria, Vivax Clinical Trial

Official title:
A Randomized, Open-label, Single-period, Parallel-group Study in Healthy Subjects to Determine the Effects of Dissolution Profile on the Pharmacokinetics (Via Both Venous and Peripheral Micro-samples) of Single Oral 300 mg Doses of Tafenoquine (SB-252263) Tablets + 30 mg Tafenoquine Stable Isotope Labelled (SIL) Solution

Clinical Trial Summary

This study will investigate the effect of Tafenoquine (TQ) 150 mg tablet ageing (dissolution profiles) on human exposure of TQ comparing the relative bioavailability of TQ from tablets exhibiting different dissolution profiles in healthy subjects. This is a single-centre, 2-arm, randomized open-label, parallel-group study in healthy subjects. All subjects will arrive in the unit approximately 24 hours prior to dosing and will be discharged after the 72-hour post-dose assessments are completed. Subjects will return for outpatient visits on Days 7, 14, 21, 28, and 56 after dosing. A total of 14 subjects (n=7 subjects in each arm) are planned to be enrolled. All subjects will receive a single dose of study medication (2x150 mg TQ tablets + 30 mg TQ SIL in solution) and participate through a 56-day post dose follow-up visit. To enable the application of peripheral microsampling in planned paediatric studies, a comparison of the measured pharmacokinetic (PK) exposure via peripheral blood collection (via microsampling) to venous collection will also be performed in this study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02751294
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date May 2016
Completion date August 2016
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05096702 - Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
Recruiting NCT05540470 - Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield N/A
Active, not recruiting NCT04079621 - Short Course Radical Cure of P. Vivax Malaria in Nepal Phase 4
Completed NCT03307369 - A Retrospective Study of Severe Plasmodium Vivax
Completed NCT01213966 - Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection Phase 2
Completed NCT00811096 - Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax Phase 2
Terminated NCT03337152 - Assessing a Risk Model for G6PD Deficiency Phase 4
Completed NCT05753150 - Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand
Recruiting NCT05058885 - Plasmodium Vivax Among Duffy Negative Population in Cameroon.
Completed NCT03377296 - Study of Controlled Human Plasmodium Vivax Infection N/A
Completed NCT00486694 - Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria Phase 2
Recruiting NCT05788094 - ACT vs CQ With Tafenoquine for P. Vivax Mono-infection Phase 4
Terminated NCT02110784 - Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria Phase 2
Not yet recruiting NCT05690841 - FocaL Mass Drug Administration for Vivax Malaria Elimination Phase 3
Not yet recruiting NCT04739917 - Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers Phase 2
Completed NCT03208907 - DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil Phase 3
Completed NCT02184637 - A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate Phase 1
Completed NCT01928914 - Tafenoquine Thorough QTc Study in Healthy Subjects Phase 1
Completed NCT01081847 - Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants Phase 1
Completed NCT00157885 - A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia. N/A